(HealthDay News) — Patients receiving high-dose recombinant human bone morphogenetic protein-2 (rhBMP-2) as part of spine surgery have an increased risk of cancer and may be at risk for major ...
Recombinant bone morphogenetic protein-2 (rhBMP-2, Medtronic Inc), used to promote bone growth in spinal fusion surgery, offers little or no benefit over bone graft and may be associated with more ...
MINNEAPOLIS--(BUSINESS WIRE)-- Following is a statement from Omar Ishrak, chairman and chief executive officer of Medtronic, Inc. (NYSE: MDT) on a series of articles on recombinant human Bone ...
MINNEAPOLIS--(BUSINESS WIRE)-- Medtronic, Inc. [NYSE: MDT] announced today that it has provided a grant to Yale University to conduct two fully independent, third-party systematic reviews of the ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio ORLANDO, Fla. — During a 2.5-year period, ...
To determine if use of an osteogenic agent (rhBMP-2) at the time of surgical treatment for tibial pseudarthosis in NF1 patients will result in improved bone healing when compared to NF1 patients ...
Self-Management of Low Back Pain Has Small Effects For patients with lumbar spondylosis or spondylolisthesis of the lowest lumbar levels who undergo open anterior lumbar interbody fusion (ALIF), use ...
LEWISVILLE, Texas--(BUSINESS WIRE)-- Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced a strategic partnership agreement with ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Compared with patients who undergo single ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results